[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652403":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":33,"locations":39,"responsibleParty":206,"collaborators":208,"id":212,"slug":213,"hasResults":214,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":11,"eligibilityCriteria":218,"healthyVolunteers":214,"sex":219,"minAge":220,"maxAge":221,"enrollmentInfo":222,"targetDuration":11,"studyType":225,"phases":226,"briefSummary":228,"conditions":229,"keywords":231,"overallStatus":42,"whyStopped":11,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":243},{"fullName":5,"class":6},"Longhua Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"LineMatrix® Biological vascular graft","EXPERIMENTAL",null,[13],"Device: LineMatrix® Biological Vascular Graft",{"label":15,"type":16,"description":11,"interventionNames":17},"GORE-INTERING®","ACTIVE_COMPARATOR",[18],"Device: GORE-INTERING®",[20,24],{"type":21,"name":22,"description":22,"armGroupLabels":23,"otherNames":11},"DEVICE","LineMatrix® Biological Vascular Graft",[9],{"type":21,"name":15,"description":15,"armGroupLabels":25,"otherNames":11},[15],[27,30],{"name":28,"affiliation":5,"role":29},"Yaxue Shi","PRINCIPAL_INVESTIGATOR",{"name":31,"affiliation":32,"role":29},"Hua Li","Sir Run Run Shaw Hospital",[34],{"name":35,"role":36,"phone":37,"phoneExt":11,"email":38},"Xuefeng Qiu","CONTACT","+8613507192551","xuefeng_qiu@humatrix-medical.com",[40,58,72,86,100,114,128,142,156,169,183,196],{"facility":41,"status":42,"city":43,"state":44,"zip":11,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Beijing Haidian Hospital","RECRUITING","Beijing","Beijing Municipality","China","CN",{"type":48,"coordinates":49},"Point",[50,51],116.39723,39.9075,{"lat":51,"lon":50},[54],{"name":55,"role":36,"phone":56,"phoneExt":11,"email":57},"Yuzhu Wang","+8618701387950","wyz4417@126.com",{"facility":59,"status":42,"city":60,"state":61,"zip":11,"country":45,"countryCode":46,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"The First Affiliated Hospital of Chongqing Medical University","Chongqing","Chongqing Municipality",{"type":48,"coordinates":63},[64,65],106.55771,29.56026,{"lat":65,"lon":64},[68],{"name":69,"role":36,"phone":70,"phoneExt":11,"email":71},"Ziming Wan","+8618696635322","wanziming-001@163.com",{"facility":73,"status":42,"city":74,"state":75,"zip":11,"country":45,"countryCode":46,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"South China Hospital of Shenzhen University","Shenzhen","Guangdong",{"type":48,"coordinates":77},[78,79],114.0683,22.54554,{"lat":79,"lon":78},[82],{"name":83,"role":36,"phone":84,"phoneExt":11,"email":85},"Yangdong Liu","+8618996353520","liuyangdong06@163.com",{"facility":87,"status":42,"city":88,"state":89,"zip":11,"country":45,"countryCode":46,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"The First Hospital of Hebei Medical University","Shijiazhuang","Hebei",{"type":48,"coordinates":91},[92,93],114.47861,38.04139,{"lat":93,"lon":92},[96],{"name":97,"role":36,"phone":98,"phoneExt":11,"email":99},"Lihong Zhang","+8618633888311","cpx1998@sina.com",{"facility":101,"status":42,"city":102,"state":103,"zip":11,"country":45,"countryCode":46,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"The First Affiliated Hospital of Zhengzhou University","Zhengzhou","Henan",{"type":48,"coordinates":105},[106,107],113.64861,34.75778,{"lat":107,"lon":106},[110],{"name":111,"role":36,"phone":112,"phoneExt":11,"email":113},"Pei Wang","+8613523467291","wangpei146@hotmail.com",{"facility":115,"status":42,"city":116,"state":117,"zip":11,"country":45,"countryCode":46,"cosmosGeoPoint":118,"geoPoint":122,"contacts":123},"Tongji Hospital Affiliated to Tongji Medical Collage of Huazhong University of Science and Technology","Wuhan","Hubei",{"type":48,"coordinates":119},[120,121],114.26667,30.58333,{"lat":121,"lon":120},[124],{"name":125,"role":36,"phone":126,"phoneExt":11,"email":127},"Gang Xu","+8613507181312","xugangtjh@163.com",{"facility":129,"status":42,"city":130,"state":131,"zip":11,"country":45,"countryCode":46,"cosmosGeoPoint":132,"geoPoint":136,"contacts":137},"The Second Affiliated Hospital of Nanjing Medical University","Nanjing","Jiangsu",{"type":48,"coordinates":133},[134,135],118.77778,32.06167,{"lat":135,"lon":134},[138],{"name":139,"role":36,"phone":140,"phoneExt":11,"email":141},"Hong Ye","+8613082552804","yehong@njmu.edu.cn",{"facility":143,"status":42,"city":144,"state":145,"zip":11,"country":45,"countryCode":46,"cosmosGeoPoint":146,"geoPoint":150,"contacts":151},"The First Affiliated Hospital of Nanchang University","Nanchang","Jiangxi",{"type":48,"coordinates":147},[148,149],115.85306,28.68396,{"lat":149,"lon":148},[152],{"name":153,"role":36,"phone":154,"phoneExt":11,"email":155},"Yan Yan","+8613879190111","kiddoc@163.com",{"facility":157,"status":42,"city":158,"state":159,"zip":11,"country":45,"countryCode":46,"cosmosGeoPoint":160,"geoPoint":164,"contacts":165},"Longhua Hospital Shanghai University of Traditional Chinese Medicine","Shanghai","Shanghai Municipality",{"type":48,"coordinates":161},[162,163],121.45806,31.22222,{"lat":163,"lon":162},[166],{"name":28,"role":36,"phone":167,"phoneExt":11,"email":168},"+8613918331840","drshiyaxue@163.com",{"facility":170,"status":42,"city":171,"state":172,"zip":11,"country":45,"countryCode":46,"cosmosGeoPoint":173,"geoPoint":177,"contacts":178},"The First Affiliated Hospital of Xi'an Jiaotong University","Xi’an","Shanxi",{"type":48,"coordinates":174},[175,176],113.52486,35.99785,{"lat":176,"lon":175},[179],{"name":180,"role":36,"phone":181,"phoneExt":11,"email":182},"Shifeng Yang","+8618092024077","nickpet12@126.com",{"facility":184,"status":42,"city":185,"state":186,"zip":11,"country":45,"countryCode":46,"cosmosGeoPoint":187,"geoPoint":191,"contacts":192},"Sir Run Run Shaw Hospital, Zhejiang University School of Medicine","Hangzhou","Zhejiang",{"type":48,"coordinates":188},[189,190],120.16142,30.29365,{"lat":190,"lon":189},[193],{"name":31,"role":36,"phone":194,"phoneExt":11,"email":195},"+8613588706757","lihua@srrsh.com",{"facility":197,"status":42,"city":185,"state":186,"zip":11,"country":45,"countryCode":46,"cosmosGeoPoint":198,"geoPoint":200,"contacts":201},"The FIrst Affiliated Hospital, College of Medicine, Zhejiang University",{"type":48,"coordinates":199},[189,190],{"lat":190,"lon":189},[202],{"name":203,"role":36,"phone":204,"phoneExt":11,"email":205},"Hua Jiang","+8613868057536","zyjianghua@163.com",{"type":29,"investigatorFullName":28,"investigatorTitle":207,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"MD",[209],{"name":210,"class":211},"Humatrix Medical Technology (Suzhou) Co., LTD","UNKNOWN","100652403","linematrix-biological-vascular-graft-for-the-creation-of-arteriovenous-graft-100652403",false,"NCT07773051","LineMatrix® Biological Vascular Graft for the Creation of Arteriovenous Graft","A Prospective, Multicenter, Randomized, Controlled, Non-inferiority Clinical Trial to Evaluate the Safety and Efficacy of LineMatrix® Biological Vascular Graft for the Creation of Arteriovenous Graft","Inclusion Criteria:\n\n* (1) Age ≥18 years and ≤80 years, male or female;\n* (2) Diagnosed with end-stage renal disease (ESRD) requiring maintenance hemodialysis;\n* (3) Requiring establishment of a long-term hemodialysis vascular access but unable to have a autologous arteriovenous fistula (AVF) created;\n* (4) Assessed by the investigator as suitable for implantation of an arteriovenous graft (AVG) in the upper extremity;\n* (5) Able to understand the purpose of the study, voluntarily participating and providing signed informed consent(ICF), and willing to comply with all scheduled follow-up assessments.\n\nExclusion Criteria:\n\n* (1) Known or suspected history of allergy to heparin, alcohol, or bovine-derived products;\n* (2) Planned to undergo renal transplantation or transition to peritoneal dialysis within 1 year;\n* (3) Hemoglobin concentration \\\u003C60 g\u002FL, or platelet count \\\u003C60 × 10⁹\u002FL;\n* (4) Left ventricular ejection fraction (LVEF) \\\u003C30%;\n* (5) Severe cardiac disease, including New York Heart Association (NYHA) Class III-IV severe heart failure, or history of myocardial infarction, unstable angina, or sustained ventricular tachyarrhythmia requiring continuous treatment within 6 months prior to enrollment;\n* (6) History of stroke within 1 month prior to enrollment;\n* (7) Uncontrolled or poorly controlled diabetes mellitus (preoperative glycated hemoglobin \\>10%);\n* (8) Immunodeficiency disorders, or current treatment with corticosteroids (prednisone-equivalent dose ≥10 mg) or immunosuppressive agents (e.g., sirolimus, mycophenolate mofetil, cyclosporine, cyclophosphamide, tacrolimus);\n* (9) Malignancy or other severe systemic disease with a life expectancy of \\\u003C12 months;\n* (10) Heparin-induced thrombocytopenia type II (HIT-2) or other contraindications to heparin use;\n* (11) Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\>2 × upper limit of normal (ULN);\n* (12) Coagulation disorders (activated partial thromboplastin time \\[APTT\\] or prothrombin time \\[PT\\] \\>1.5 × ULN);\n* (13) Systemic or surgical site infection (white blood cell \\[WBC\\] count \\>15 × 10⁹\u002FL);\n* (14) Baseline hypotension, or frequent hypotensive episodes within the past month (frequency ≥5 episodes\u002Fmonth, with hypotension defined as systolic blood pressure \\\u003C90 mmHg or diastolic blood pressure \\\u003C60 mmHg);\n* (15) Hypercoagulable state, or history of ≥2 episodes of deep vein thrombosis or peripheral vascular thrombosis not related to dialysis access;\n* (16) Known ipsilateral central venous stenosis, or clinical symptoms\u002Fsigns suggestive of central venous stenosis confirmed by imaging;\n* (17) Severe mental disorders that preclude cooperation with the study protocol;\n* (18) Pregnant or lactating women, or women of childbearing potential who plan to conceive during the trial and are unwilling to use effective contraception;\n* (19) Currently enrolled in another drug or medical device clinical trial and not yet completed the study;\n* (20) Any other conditions that, in the investigator's opinion, make the patient unsuitable for participation in this clinical trial.","ALL","18 Years","80 Years",{"count":223,"type":224},326,"ESTIMATED","INTERVENTIONAL",[227],"NA","The study is planned to be conducted at multiple centers, with an intended enrollment of 326 subjects. Protocol-eligible subjects will be randomized in a 1:1 ratio to either the investigational group or the control group. The investigational group will receive a Biological Vascular Graft(LineMatrix®) manufactured by Humatrix Medical Technology (Suzhou) Co., LTD, while the control group will receive an arteriovenous graft (GORE-INTERING®) manufactured by W.L. Gore \\& Associates, Inc. The primary endpoints are the Primary patency rate at 6 months postoperatively and the Cumulative Patency Rate at 12 Months postoperatively. Subjects will undergo follow-up during the screening period, at the time of AVG procedure, and at 1 month, 3 months, 6 months, and 12 months post-operatively. Safety and efficacy parameters will be observed and recorded during and after the surgery to evaluate the safety and effectiveness of the LineMatrix® Biological Vascular Graft for the creation of arteriovenous graft in patients with end-stage renal disease (ESRD).",[230],"Arteriovenous Graft",[230,232,233],"Hemodialylsis","End Stage Kidney Disease(ESKD)","2026-08-15",{"date":236,"type":237},"2026-08-19","ACTUAL",{"date":239,"type":237},"2025-08-25",{"date":241,"type":224},"2027-09-30",{"name":5,"class":6},12]